Medtronic : Proposed Infuse™ TLIF indication granted Breakthrough Device designation by FDA

Medtronic, a global leader in medical technology, announced today that it has received U.S. FDA Breakthrough Device designation for Infuse™ bone graft with an intervertebral fusion device and a commercially available metallic screw and rod system. This designation pertains to the use of Infuse™ bone graft in a transforaminal lumbar interbody fusion (TLIF) surgical approach at one or two adjacent levels from L2 - S1 in the treatment of degenerative disease of the lumbosacral spine. The FDA [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.